세계의 해부 병리학 시장 예측(-2032년) : 제품별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Anatomic Pathology Market is accounted for $38.78 billion in 2025 and is expected to reach $84.14 billion by 2032 growing at a CAGR of 11.7% during the forecast period. Anatomic pathology is a medical specialty focused on diagnosing diseases by examining tissues, organs, and cells removed from the body. It involves techniques such as gross examination, microscopic analysis, and advanced lab testing to identify abnormalities, including tumors, infections, and structural changes. Anatomic pathologists play a crucial role in guiding clinical decisions by providing precise diagnostic information that supports patient management, treatment planning, and disease monitoring across various medical fields.

According to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide.

Market Dynamics:

Driver:

Growing adoption of personalized medicine

As treatments become more tailored to individual patient profiles, clinicians rely heavily on precise tissue analysis to guide decision-making. Molecular pathology and biomarker-driven testing are expanding, enhancing the accuracy of therapeutic selections. Integration of digital pathology and AI-based tools is enabling faster and more detailed diagnostic insights. Healthcare providers are increasingly investing in specialized pathology services to support individualized treatment strategies. This shift toward precision care is expected to continue strengthening the market's long-term growth.

Restraint:

Shortage of skilled pathologists and technicians

Many healthcare facilities face delays due to high workloads and limited expert availability. The growing complexity of diagnostic procedures further increases the demand for specialized skill sets. Training programs are not expanding quickly enough to meet rising diagnostic volumes. As a result, turnaround times may lengthen, affecting clinical decision-making. This workforce gap continues to pose operational challenges for institutions worldwide.

Opportunity:

Rising demand for companion diagnostics (CDx)

Increasing adoption of targeted therapies is accelerating the need for companion diagnostics in anatomic pathology. These tests help determine the suitability of specific drugs based on individual patient biomarkers. Growth in oncology pipelines is further driving CDx integration into clinical workflows. Advancements in tissue profiling technologies are enhancing the accuracy of predictive testing. Regulatory approvals for CDx-linked treatments are expanding across global markets. This rising demand is opening significant opportunities for pathology providers and diagnostic developers.

Threat:

Threat of substitute products/techniques

Liquid biopsy methods are gaining attention due to their non-invasive nature and faster turnaround times. Advancements in imaging-based diagnostics are also challenging traditional tissue examination. Some healthcare providers may shift toward these substitutes to streamline diagnostics. Rapid technological innovations could further reduce reliance on conventional pathology approaches. This competitive environment may limit growth for providers who do not adapt to evolving trends.

Covid-19 Impact:

The COVID-19 pandemic disrupted laboratory workflows and slowed elective diagnostic procedures in many facilities. Pathology departments faced reduced case volumes and delays in routine testing. However, the crisis accelerated digital pathology adoption and remote diagnostic review models. Laboratories invested in automation and cloud-based systems to maintain service continuity. Post-pandemic strategies now emphasize stronger infrastructure, workforce flexibility, and technology-enabled diagnostics.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period, driven by rising outsourcing of diagnostic testing to specialized pathology laboratories. Healthcare providers rely on these services for advanced molecular and histopathological analyses. Service providers offer comprehensive testing workflows without requiring hospitals to invest in costly equipment. Their capabilities in digital pathology and rapid reporting further drive demand.

The hospitals & ambulatory surgical centers (ASCs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & ambulatory surgical centers (ASCs) segment is predicted to witness the highest growth rate, due to rising patient admissions and expanding surgical procedures are increasing the demand for onsite pathology support. Many facilities are adopting digital pathology platforms to speed up diagnostic decisions. Investments in modern laboratory infrastructure are helping hospitals reduce reliance on external diagnostic centers. Adoption of AI-enabled tools is improving workflow efficiency and accuracy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to strong healthcare infrastructure and high diagnostic testing volumes support this dominance. The region benefits from early adoption of digital pathology and AI-driven diagnostic tools. Large investments in cancer research and biomarker development further strengthen market growth. Favorable reimbursement policies encourage widespread use of advanced pathology services.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to expanding healthcare systems and rising awareness of early disease diagnosis are fueling demand. Countries such as China and India are investing heavily in modern laboratory technologies. Growing incidences of cancer are accelerating the adoption of advanced pathology services. Public and private sector collaborations are improving diagnostic accessibility in emerging markets.

Key players in the market

Some of the key players in Anatomic Pathology Market include Roche Dia, Becton, Di, Thermo Fi, Hologic In, Agilent Te, PerkinElm, Danaher Co, Abbott Lab, Sakura Fin, Merck KGa, BioGenex, Cardinal H, Quest Dia, Laborator, and NeoGeno.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients.

In April 2025, Thermo Fisher Scientific has introduced the Thermo Scientific(TM) Krios(TM) 5 Cryo-TEM. This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable.

Products Covered:

• Instruments
• Consumables
• Services

Techniques Covered:

• Histology
• Coagulation Tests
• Immunohistochemistry (IHC)
• Serology & Immunology
• Molecular Pathology
• Blood Routine Examination

Applications Covered:

• Disease Diagnosis
• Drug Discovery & Development
• Other Applications

End Users Covered:

• Hospitals & Ambulatory Surgical Centers (ASCs)
• Clinical & Diagnostic Laboratories
• Research Institutes
• Blood Banks
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Anatomic Pathology Market, By Product

• 5.1 Introduction
• 5.2 Instruments
  • 5.2.1 Microtomes
  • 5.2.2 Stainers
  • 5.2.3 Tissue Processing Systems
• 5.3 Consumables
  • 5.3.1 Reagents
  • 5.3.2 Slides & Cassettes
  • 5.3.3 Kits
• 5.4 Services
  • 5.4.1 Histopathology Services
  • 5.4.2 Immunohistochemistry Services
  • 5.4.3 Cytopathology Services
  • 5.4.4 Digital Pathology Services

6 Global Anatomic Pathology Market, By Technique

• 6.1 Introduction
• 6.2 Histology
• 6.3 Coagulation Tests
• 6.4 Immunohistochemistry (IHC)
• 6.5 Serology & Immunology
• 6.6 Molecular Pathology
• 6.7 Blood Routine Examination

7 Global Anatomic Pathology Market, By Application

• 7.1 Introduction
• 7.2 Disease Diagnosis
  • 7.2.1 Oncology
  • 7.2.2 Infectious Diseases
  • 7.2.3 Chronic Conditions
• 7.3 Drug Discovery & Development
• 7.4 Other Applications

8 Global Anatomic Pathology Market, By End User

• 8.1 Introduction
• 8.2 Hospitals & Ambulatory Surgical Centers (ASCs)
• 8.3 Clinical & Diagnostic Laboratories
• 8.4 Research Institutes
• 8.5 Blood Banks
• 8.6 Other End Users

9 Global Anatomic Pathology Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Roche Diagnostics
• 11.2 Becton, Dickinson and Company (BD)
• 11.3 Thermo Fisher Scientific
• 11.4 Hologic Inc.
• 11.5 Agilent Technologies
• 11.6 PerkinElmer
• 11.7 Danaher Corporation
• 11.8 Abbott Laboratories
• 11.9 Sakura Finetek Japan
• 11.10 Merck KGaA
• 11.11 BioGenex Laboratories
• 11.12 Cardinal Health
• 11.13 Quest Diagnostics
• 11.14 Laboratory Corporation of America Holdings
• 11.15 NeoGenomics Laboratories